...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Anticancer Research: International Journal of Cancer Research and Treatment >Time to castration resistance is an independent predictor of castration-resistant prostate cancer survival.
【24h】

Time to castration resistance is an independent predictor of castration-resistant prostate cancer survival.

机译：去势抵抗时间是去势抵抗性前列腺癌生存的独立预测因子。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

BACKGROUND/AIM: Easily assessable clinical predictors of response to chemotherapy in advanced castration-resistant prostate cancer (CRPC) are few. The objective of this retrospective study was to search for and identify such candidate predictors of outcome. PATIENTS AND METHODS: A retrospective analysis of clinical data of CRPC patients entered in the Clinical Therapeutics' departmental prostate cancer database from 1996-2009 was performed. Univariate and multivariate analyses for progression-free survival and overall survival included patients receiving both docetaxel- and non-docetaxel-containing regimens. RESULTS: From 1996 until June 2009, 286 out of 313 patients in our database were treated with chemotherapy. Prostate-specific antigen (PSA) reduction >30% correlated with improved survival irrespective of treatment. Beyond previously reported predictors, i.e. baseline PSA >30 ng/dl, hemoglobin below 10 mg/dl, weight loss, poor performance status, elevated lactic dehydrogenase and alkaline phosphatase, and time to CRPC of less than or equal to two years was associated with a poor overall survival and shorter progression-free survival upon univariate analysis. Pain was associated with shorter survival. Multivariate analysis confirmed time to CRPC, lactate dehydrogenase and alkaline phosphatase as independent predictors of overall and progression-free survival. CONCLUSION: Time to castration resistance is an important predictor of outcome in CRPC. PSA reduction >30% predicts survival improvement following chemotherapy for CRPC regardless of chemotherapy applied.
机译：背景/目的：在晚期去势抵抗性前列腺癌（CRPC）中，对化疗反应的容易评估的临床预测因素很少。这项回顾性研究的目的是寻找并确定此类候选预后指标。病人与方法：对1996-2009年进入临床治疗学部门前列腺癌数据库的CRPC患者的临床数据进行回顾性分析。无进展生存期和总生存期的单因素和多因素分析包括接受多西他赛和不接受多西他赛方案的患者。结果：从1996年到2009年6月，我们数据库中的313例患者中有286例接受了化疗。前列腺特异性抗原（PSA）降低> 30％与改善生存率相关，而与治疗无关。与先前报道的预测指标不同，即基线PSA> 30 ng / dl，血红蛋白低于10 mg / dl，体重减轻，体能状况差，乳酸脱氢酶和碱性磷酸酶升高以及CRPC时间小于或等于两年与单因素分析显示总体生存率较差，无进展生存期较短。疼痛与生存期短有关。多变量分析证实了CRPC，乳酸脱氢酶和碱性磷酸酶的时间是总体生存和无进展生存的独立预测指标。结论：去势抵抗时间是CRPC结局的重要预测指标。 PSA降低> 30％可以预测CRPC化疗后的生存率提高，无论采用何种化疗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号